查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎治療和診斷全球市場：按治療劑、診斷劑、地區劃分——規模、份額、展望、機會分析，2023-2030
市場調查報告書
商品編碼
1233324

非酒精性脂肪性肝炎治療和診斷全球市場：按治療劑、診斷劑、地區劃分——規模、份額、展望、機會分析，2023-2030

Non-alcoholic Steatohepatitis Therapeutics and Diagnostics Market, By Therapeutics, By Diagnostics, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

非酒精性脂肪性肝炎 (NASH) 是由肝臟中過多的脂肪細胞引起的肝臟炎症（脂肪肝病）。 當多餘的脂肪變成肝臟炎症（肝臟腫脹）和纖維化（疤痕）時，就會發生這種情況。 由於 NASH 是一種隱性流行病，因此對安全有效的治療和診斷的需求不斷增長。

市場動態

患有 NASH 的人口不斷增加，糖尿病和肥胖人口不斷增加，對安全有效的 NASH 治療和診斷的需求不斷增加，政府和非政府組織的積極參與，對 NAFLD/NASH 的認識不斷提高，這些都是預計將推動增長的關鍵因素預測期內全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場。

例如，2022 年 6 月，Echosens 和 Novo Nordisk A/S 將推進非酒精性脂肪性肝炎 (NASH) 的早期診斷，並在患者、醫療保健提供者和其他利益相關者中進行推廣。宣布合作以提高對非酒精性脂肪性肝炎 (NASH) 的認識疾病。 2018 年 6 月，世界肝臟研究所發起了第一個國際 NASH 日，以提高人們對 NASH 的認識以及人們可以採取的預防措施。

這項研究的主要特點

  • 本報告對全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場進行了深入分析，其中包括以 2022 年為基準年的預測期（2023-2030 年）的市場規模和年復合數據。我們提供增長率（CAGR %）。
  • 它還闡明了各個細分市場的潛在創收機會，並描述了該市場具有吸引力的投資建議矩陣。
  • 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
  • 根據以下參數對全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場的主要參與者進行了介紹，這些參數包括公司亮點、產品組合、主要亮點、財務業績和戰略執行情況。
  • 本研究涵蓋的主要公司包括
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 《全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。與
  • 利益相關者可以通過用於分析全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場的各種戰略矩陣來促進決策制定。

這是目錄。

第一章調查的目的和前提

  • 調查目的
  • 先決條件
  • 縮寫

第二章市場範圍

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 按治療劑分類的市場概況
    • 市場概況：按診斷劑分類
    • 市場概況：按地區
  • 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 全球 NASH 患者人數增加
    • 治療領域進展緩慢
    • 對安全有效的治療和診斷的需求不斷增長
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/批准
  • 害蟲分析
  • 對 PORTER 的分析
  • 合併/收購場景

第 4 章非酒精性脂肪性肝炎 (NASH) 藥物和診斷的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 流行病學
  • 供應方和需求方分析
  • 經濟影響

第 5 章非酒精性脂肪性肝炎 (NASH) 藥物和診斷的全球市場：2017-2030

  • Elafibranol
  • 奧卡裡巴
  • Theronsertive
  • Senikriviroku
  • 埃姆利卡桑
  • 其他治療藥物

第 6 章。全球非酒精性脂肪性肝炎 (NASH) 藥物和診斷劑市場：2017-2030

  • 成像技術
  • 診斷測試
  • 活檢

第 7 章按地區分列的非酒精性脂肪性肝炎 (NASH) 藥物和診斷的全球市場，2017-2030

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
  • 世界其他地區

第八章競爭格局

  • Novartis AG
  • Allergan Plc.
  • Viking Therapeutics
  • Merck & Co.
  • Zydus Cadila
  • Novo Nordisk A/S
  • GENFIT SA
  • Gilead Sciences Inc.
  • Galmed Pharmaceuticals
  • Madrigal Pharmaceuticals
  • Intercept Pharmaceuticals Inc.

第 9 章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI2279

Non-alcoholic steatohepatitis (NASH) is inflammation of the liver caused by excess fat cells in it (fatty liver disease). It is caused when that extra fat turns into inflammation (swelling in the liver) and fibrosis (scarring) of the liver. NASH is a hidden epidemic, and thus, there is an increase demand for safe and effective therapeutics and diagnostics.

Market Dynamics:

Rise in NASH-affected population, increase in diabetic and obese population, increase in demand for safe and effective NASH therapeutics and diagnostics, favorable initiatives by government and non-government organizations, and increasing awareness about NAFLD/NASH are major factors expected to propel the growth of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

For instance, in June 2022, Echosens and Novo Nordisk A/S announced a collaboration to advance the early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers, and other stakeholders. In June 2018, the first International NASH Day was launched by Global Liver Institute with the goal of raising awareness about NASH and the actions people can take to prevent the disease.

Key features of the study:

  • This report provides in-depth analysis of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market.

Detailed Segmentation:

  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics:
    • Elafibranor
    • Ocaliva
    • Selonsertib
    • Cenicriviroc
    • Emricasan
    • Other Therapeutics
  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics:
    • Imaging Techniques
    • Diagnostic Tests
    • Biopsy
  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Novartis AG
    • Allergan Plc.
    • Viking Therapeutics
    • Merck & Co.
    • Zydus Cadila
    • Novo Nordisk A/S
    • GENFIT SA
    • Gilead Sciences Inc.
    • Galmed Pharmaceuticals
    • Madrigal Pharmaceuticals
    • Intercept Pharmaceuticals Inc.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapeutics
    • Market Snapshot, By Diagnostics
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in NASH-affected population worldwide
    • Slow advancements in the therapeutic field
    • Rise in demand for safe/effective therapeutics and diagnostics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Elafibranor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Ocaliva
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Selonsertib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Cenicriviroc
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Emricasan
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other Therapeutics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Imaging Techniques
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Diagnostic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Biopsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Geography, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)

8. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Allergan Plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viking Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zydus Cadila
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk A/S
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GENFIT SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Gilead Sciences Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Galmed Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Madrigal Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Intercept Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Analyst Views

9. Section

  • Research Methodology
  • About us